NEWAMSTERDAM PHARMA CO NV

Inside NewAmsterdam Pharma’s July 20 insider trades reveal a strategic buy‑low, sell‑high pattern that signals confidence, liquidity needs, and future growth in the cardiovascular space.

Insider trading by Newamsterdam Pharma’s director shows a hedging strategy that preserves capital while signaling confidence in the firm’s long‑term prospects.

CEO buys shares in Newamsterdam Pharma amid Phase‑III CLL study; insider buying signals confidence while investors watch upcoming trial data and FDA review.

Newamsterdam Pharma insider buying signals future upside as NAM‑01 phase‑2 trials show 1.3% HbA1c drop and a potential 160% gain if Phase‑3 succeeds.

Newamsterdam insider Kooij Louise Frederika buys 38,172 shares at $10.90, 5.1% stake rise, hinting confidence amid sales‑buy cycle strategy.

Newamsterdam Pharma CFO’s Rule‑10b5‑1 buy signals confidence in early‑stage heart‑failure drug; investors should watch Phase III milestones and regulatory filings for true value.